신생혈관성 나이관련황반변성에서 베바시주맙 주입과 광역학요법을 병합한 일차치료 효과

• 영문명: Primary Combined Photodynamic Therapy and Intravitreal Bevacizumab Injection for Neovascular Age-related Macular Degeneration
• 발행기관: 대한안과학회
• 저자명: 유영주 박혜진 이태곤 이동원 조성원 이재흥,Young Ju Lew, MD, PhD, Hae Jin Park, MD, Tae Gon Lee, MD, Dong Won Lee, MD, PhD,Sung Won Cho, MD, PhD, Jae Heung Lee, MD, PhD
• 간행물 정보: 『대한안과학회지』Ophthalmological Society,volume51,number1, 35~41쪽, 전체 7쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2010.01.15

영문 초록

Purpose: To investigate the efficacy of the combined treatment of photodynamic therapy (PDT) with verteporfin and intravitreal bevacizumab in patients with neovascular age-related macular degeneration. Methods: Forty-five eyes received a single session of PDT following three intravitreal bevacizumab (1.25 mg) injections at six-week intervals (IVB+PDT group). Twenty-seven eyes received three intravitreal bevacizuamb (1.25 mg) injections only at six-week intervals (IVB group). Results: After the six months of follow up, the mean BCVA (LogMAR) changed significantly from 0.62±0.34 to 0.56±0.33 in the IVB group (p=0.03) and from 0.61±0.33 to 0.48±0.21 in the IVB+PDT group (p=0.001). The mean BCVA was more improved in the IVB+PDT group (p=0.049). The mean CMT changes were significant in both groups immediately after treatment, but there was no significant difference at six months between the two groups. Ten eyes (37.0%) in the IVB group and 12 eyes (26.7%) in the IVB+PDT group required retreatments during the six months of follow-up (p=0.02). Conclusions: Significant improvement in visual acuity and reduction in central macular thickness over a six-months period were observed in both groups. The mean visual acuity was significantly better and the rate of reinjections after the initial treatment schedule was lower in the IVB+PDT group. J Korean Ophthalmol Soc 2010;51(1):35-41

키워드

Age-related macular degeneration, Bevacizumab, Choroidal neovascularization, Photodynamic therapy